Epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) are important milestones in the development of tumor‐targeted therapy and have greatly improved outcomes for NSCLC patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.